Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 03/18/19
End: 03/16/21
Due: 03/16/22
Phase: N/A
Priority: Normal
Start: 12/13/22
End: 11/30/27
Due: 11/30/28
Phase: N/A
Priority: Normal
Start: 11/10/20
End: 12/17/20
Due: 12/17/21
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A Phase Ia/Ib, SAD and MAD Study of of KL1333 in Healthy Subjects and Patients With Primary Mitochondrial Disease | NCT03888716 | Abliva AB | user2@example.com | None | 2019-03-18 | 2021-03-16 | 2022-03-16 | - | - | 2025-07-14 |
| Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease | NCT05650229 | Abliva AB | user2@example.com | None | 2022-12-13 | 2027-11-30 | 2028-11-30 | - | - | 2025-07-14 |
| Drug-drug Interaction Study of KL1333 in Healthy Subjects | NCT04643249 | Abliva AB | user2@example.com | None | 2020-11-10 | 2020-12-17 | 2021-12-17 | - | - | 2025-07-14 |